Success Stories

Sanofi and Regeneron announce the U.S. Food and Drug Administration approved Praluent (alirocumab) Injection, the first PCSK9 Inhibitor in the U.S., for the treatment of High LDL Cholesterol in adult patients. See link below:

http://www.news.sanofi.us/2015-07-24-Sanofi-and-Regeneron-Announce-FDA-Approval-of-Praluent-alirocumab-Injection-the-First-PCSK9-Inhibitor-in-the-U-S-for-the-Treatment-of-High-LDL-Cholesterol-in-Adult-Patients